Chintu Patel - Mar 3, 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Co-CEO, Director
Signature: Nikita Shah, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/7/2023, 05:00 PM
Previous filing: Mar 3, 2022
Next filing: Nov 8, 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+734K		$0.00	734K	Mar 3, 2023	Class A Common Stock	734K		Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2	Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period.

Content

Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period.